

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hiroshi NISHIYAMA, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/JP05/01518

GAU:

FILED: Herewith

EXAMINER:

FOR: DRUG FOR INHIBITING VASCULAR INTIMAL HYPERPLASIA

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 293275US0X PCT		SERIAL NO. 35949	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hiroshi NISHIYAMA, et al.			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	91/16314	10/31/91	WO (with English abstract, equivalent of US5314883, US5202323 & US5318968)		NO	
	AP	7-252237	10/03/95	JP (US5856327 & US5750523)		NO	
	AQ	00/33845	06/15/00	WO (with English abstract)		NO	
	AR	9-157258	06/17/97	JP (equivalent of US6143763)		NO	
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	UEHARA, Kenji et al., "Phosphodiesterase 3 Sogaizai no Kodomyaku Koka Sayo, The Cell, Vol. 30, No. 5, Pages 197 to 200, 1998.					
	AX	HACHISU, Mitsugu et al., "Sentakuteki Phosphodiesterase III Sogaizai Amrinone ni Yoru Rat Keidomyaku Shinsei Naimaku Hiko Yokusei Sayo", Folia Pharmacol. Jpn., Vol. 122, Pages 267 to 274, 1998. (with partial English translation)					
	AY	KIMURA, Yukio et al., "Summary of Cilostazol, a PDEIII Inhibitor., Jpn. J. Pharmacol., Vol. 85 (Suppl. 1), No. S36-1, 2001.					
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							